Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity : A prospective 1-year follow-up study
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved..
Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding α4 integrin and inhibiting leukocyte migration to the central nervous system. We recently reported an association between low natalizumab receptor occupancy and subjective wearing-off symptoms at the end of the 4-week dosing interval. Here, we aimed to evaluate the short-term risk of disease activity in a 1-year prospective follow-up of the same patient cohort (n = 40). We found that all patients available for follow-up after one year (n = 35) fulfilled the criteria for no evidence of disease activity (NEDA). Thus, wearing-off symptoms were not associated with increased short-term risk of disease activity. Longer follow-up in a larger patient cohort is required to establish whether therapeutic efficacy is maintained in patients with wearing-off symptoms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:415 |
|---|---|
| Enthalten in: |
Journal of the neurological sciences - 415(2020) vom: 15. Aug., Seite 116880 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bringeland, Gerd Haga [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 14.05.2021 Date Revised 14.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jns.2020.116880 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309964792 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309964792 | ||
| 003 | DE-627 | ||
| 005 | 20231225135051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jns.2020.116880 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM309964792 | ||
| 035 | |a (NLM)32413799 | ||
| 035 | |a (PII)S0022-510X(20)30216-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bringeland, Gerd Haga |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity |b A prospective 1-year follow-up study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.05.2021 | ||
| 500 | |a Date Revised 14.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding α4 integrin and inhibiting leukocyte migration to the central nervous system. We recently reported an association between low natalizumab receptor occupancy and subjective wearing-off symptoms at the end of the 4-week dosing interval. Here, we aimed to evaluate the short-term risk of disease activity in a 1-year prospective follow-up of the same patient cohort (n = 40). We found that all patients available for follow-up after one year (n = 35) fulfilled the criteria for no evidence of disease activity (NEDA). Thus, wearing-off symptoms were not associated with increased short-term risk of disease activity. Longer follow-up in a larger patient cohort is required to establish whether therapeutic efficacy is maintained in patients with wearing-off symptoms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Natalizumab | |
| 650 | 4 | |a Receptor occupancy | |
| 650 | 4 | |a Relapsing-remitting multiple sclerosis | |
| 650 | 4 | |a Treatment response | |
| 650 | 4 | |a Wearing-off | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Natalizumab |2 NLM | |
| 700 | 1 | |a Myhr, Kjell-Morten |e verfasserin |4 aut | |
| 700 | 1 | |a Vedeler, Christian Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Gavasso, Sonia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the neurological sciences |d 1964 |g 415(2020) vom: 15. Aug., Seite 116880 |w (DE-627)NLM000061956 |x 1878-5883 |7 nnns |
| 773 | 1 | 8 | |g volume:415 |g year:2020 |g day:15 |g month:08 |g pages:116880 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jns.2020.116880 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 415 |j 2020 |b 15 |c 08 |h 116880 | ||